Cargando…
Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
INTRODUCTION: Hair thinning occurred in 10–14% of teriflunomide-treated patients in the teriflunomide multiple sclerosis clinical development program, compared with 5% of placebo-treated patients. Our objective was to examine the clinical course of hair thinning in patients in an observational real-...
Autores principales: | Hendin Travis, Lori, Okai, Annette, Cavalier, Steve, Stam, Darren, Farnett, Lisa, Edwards, Keith R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283787/ https://www.ncbi.nlm.nih.gov/pubmed/30084001 http://dx.doi.org/10.1007/s40120-018-0107-y |
Ejemplares similares
-
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022) -
An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013) -
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020) -
Reducing return of disease activity in patients with relapsing
multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month
interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019) -
Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
por: Zivadinov, Robert, et al.
Publicado: (2020)